Tudurí Eva, Imbernon Monica, Hernández-Bautista Rene Javier, Tojo Marta, Fernø Johan, Diéguez Carlos, Nogueiras Rubén
Instituto de Investigaciones Sanitarias (IDIS)CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain.
J Mol Endocrinol. 2017 Apr;58(3):R191-R202. doi: 10.1530/JME-16-0253. Epub 2017 Feb 14.
GPR55 is a G-protein-coupled receptor (GPCR) that has been identified as a new cannabinoid receptor. Given the wide localization of GPR55 in brain and peripheral tissues, this receptor has emerged as a regulator of multiple biological actions. Lysophosphatidylinositol (LPI) is generally accepted as the endogenous ligand of GPR55. In this review, we will focus on the role of GPR55 in energy balance and glucose metabolism. We will summarize its actions on feeding, nutrient partitioning, gastrointestinal motility and insulin secretion in preclinical models and the scarce data available in humans. The potential of GPR55 to become a new pharmaceutical target to treat obesity and type 2 diabetes, as well as the foreseeing difficulties are also discussed.
GPR55是一种已被鉴定为新型大麻素受体的G蛋白偶联受体（GPCR）。鉴于GPR55在脑和外周组织中的广泛定位，该受体已成为多种生物学作用的调节因子。溶血磷脂酰肌醇（LPI）被普遍认为是GPR55的内源性配体。在本综述中，我们将聚焦于GPR55在能量平衡和葡萄糖代谢中的作用。我们将总结其在临床前模型中对进食、营养分配、胃肠蠕动和胰岛素分泌的作用以及人类中可用的稀少数据。还讨论了GPR55成为治疗肥胖症和2型糖尿病新药物靶点的潜力以及可预见的困难。
